Clínica Las Condes has completed a successful bond voluntary call option
Clínica Las Condes has completed a bond voluntary call option with the goal of reducing financial debt and interest expenses.
Based in Santiago, Chile, Clínica Las Condes is one of the largest private hospitals in the country. It initiated its operations in 1982, with a focus in high complexity medicine. Its services include inpatient medical, surgical intensive care units, intermediate, adult, pediatric, neonatal, surgical wards, post-recovery operative, clinical laboratories, radiology, CT magnetic resonance imaging, radiation therapy, PET-CT, nuclear medicine, ultrasound, dialysis and other services that include outpatient procedures.
Oaklins’ team in Chile acted as financial advisor to Clínica Las Condes.
Talk to the deal team
Related deals
MEDIK Hospital Design Group has been acquired by STERIS
The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.
Learn morebioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.
Learn moreBanook, backed by Motion Equity, has acquired Fluidda
Banook Group has acquired Fluidda NV, marking a strategic expansion into advanced in-silico trials and respiratory disease modeling. Combining Banook’s expertise in cardiac safety and clinical data services with Fluidda’s AI-driven respiratory analytics creates a powerful, integrated platform. This deal strengthens Banook’s position in the contract research organization (CRO) sector, offering pharmaceutical clients broader, technology-enabled solutions to drive drug development and reduce costs.
Learn more